Anti-Protein Tyrosine Kinase 7 (PTK7) Aptamer Synthesis and Modification Service

The lack of tumour cell specificity often leads to life-threatening toxic effects in patients receiving conventional cancer chemotherapy. To overcome this problem and improve the selectivity of cancer therapy, cytotoxic drugs can be delivered to tumour-specific sites. To achieve this goal, aptamer-linked drugs play a crucial role in targeted drug delivery. Therefore, the design of aptamers with the ability to specifically target multiple cancer cell surface receptors is of significant research interest.

CD Bioparticles offers services for the synthesis and modification of anti-PTK7 aptamers. By synthesising aptamers, we are enabling fundamental research into the role of aptamers in the delivery of specific anticancer drugs. The aptamers we produce play a crucial role in targeted cancer diagnosis and treatment. At the same time, we further modify the synthesised aptamers to provide a reference for better design of targeted drug delivery solutions.

Introduction to Anti- PTK7

Protein tyrosine kinase 7 (PTK-7) is a member of the RTK family and was originally cloned as colon cancer kinase 4 (CCRK-4), which is overexpressed in colon cancer. It is a cell membrane protein known to be overexpressed in CCRF-CEM (human T-cell ALL) cells, with seven immunoglobulin-like structural domains in the extracellular region and a tyrosine kinase-like structural domain in the intracellular region. PTK7-dependent signaling plays a key role in embryogenesis and carcinogenesis. It is present in a variety of cancers. It is expressed in colon and gastric cancers and can act as a potential receptor for targeting aptamers.

Fig. 1 Schematic diagram of differences between indirect immunofluorescence labeling (left) and aptamer probe (right) in labeling PTK7 on the cell membrane. (Chen J, et al.; 2021)

Our Anti-PTK7 Aptamer Services

CD Bioparticles is engaged in the synthesis and modification of anti-PTK7 aptamer. Our team offers services ranging from aptamer construction to aptamer modification for the study of targeted drug delivery systems. We can also tailor other types of aptamers to suit your needs. Our services include, but are not limited to, the following:

• Anti- PTK7 Aptamer Design

We will work with you to design aptamers specifically for the PTK7 receptor or any other target protein of interest.

• Anti- PTK7 Aptamer Synthesis

We offer custom anti-PTK7 aptamer synthesis services using a range of methods, including SELEX with modified bases, traditional SELEX with unmodified bases, and competitive and/or negative selection. Maturation SELEX (2nd round SELEX using a pre-screened focused library).

• Anti- PTK7 Aptamer Modifications

We can further modify anti-PTK7 aptamer to improve their binding affinity, stability, and specificity to the target protein. This includes chemical modifications, conjugation to different tags or fluorophores, and incorporation of anti-nuclease ligands.

• Characterisation of Anti- PTK7 Aptamer

A range of assays can be used to characterize the binding properties of anti-PTK7 aptamer, such as binding assay (using the RI method), competition binding assay, trimming (truncation and optimization), and ligand scan (functional study).

• Anti- PTK7 Aptamer Specificity and Affinity Analysis

Their specificity and affinity for the target are assessed using flow cytometry and microscopy.

• Anti- PTK7 Aptamer Targeted Drug Delivery

In vitro and in vivo assays are used to demonstrate that the anti-PTK7 aptamer developed can direct tissue-specific drug uptake.

• Anti- PTK7 Aptamer Optimisation

We offer optimization services to improve the properties of aptamers for your specific application. This includes optimization of the aptamer sequence, modification of the aptamer structure, and optimization of the attachment chemistry.

Contact Us

CD Bioparticles offers services for the synthesis and modification of anti-PTK7 aptamers. Coupling anti-tumour drugs with targeted agents such as aptamers can improve efficacy and reduce the overall toxicity of chemotherapy. We have developed a range of aptamers that can bind to cell surface receptors for you to choose from for drug coupling. If you are interested in our services, please do not hesitate to contact us.

Quotations and Ordering

References

1. Liu, M.; et al. Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours. Cell Prolif. 2019; 52 (1): e12511.
2. Huang, YF.; et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009; 10 (5): 862-8.
3. Chen, J.; et al. Organization of protein tyrosine kinase-7 on cell membranes characterized by aptamer probe-based storm imaging. Anal Chem. 2021; 93 (2): 936-945.